Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1701-1720 of 1,782 trials

Insomnia in Adolescents: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep in adolescents with psychiatric disorders and insomnia. We’ll also look at how these treatments affect overall well-being and daily functioning.

Psychiatric Disorders and Insomnia≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Metastatic Colorectal Cancer: New Diagnostic Test for Treatment Guidance

We are studying a new test to help doctors determine the best third-line therapy for patients with metastatic colorectal cancer. The goal is to see if this test provides accurate and reliable information for treatment decisions.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Chronic Rhinosinusitis: Stopping Treatment Study

We are investigating if patients with severe nasal polyps can safely stop treatment after a year without symptoms. We also want to see if one medication works better than the other for achieving this.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Reducing Complications After Pancreatoduodenectomy: HOP Bundle Study

We are investigating whether a combination of hydrocortisone, octreotide, and a teres ligament patch can help prevent major complications in patients undergoing high-risk pancreatoduodenectomy. This study also looks at its effect on specific complications like pancreatic fistulas.

Resectable Pancreatic Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOncologyOrthopedics and Traumatology

Oxytocin Infusion: Effects on Sensory Nerves

We are studying how intravenous oxytocin affects sensory nerve responses and cognitive performance in healthy volunteers. This research may help us understand its role in pain perception and inflammation.

Healthy Participants>2 yearsSafety phase (I)≤5 visitsStandard MedicinesNeurologyPsychiatry

Liver Surgery: Blood Clot Prevention Study

We are comparing two methods of preventing blood clots in patients undergoing liver resection. The goal is to find out which method is safer and more effective in reducing clot risks.

Liver SurgeryMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyHematologyOrthopedics and Traumatology

Vitamin D3 Supplementation: Young Adults vs. Seniors

We are comparing how vitamin D3 affects young adults and seniors to find the best supplementation approach for each group. The study also examines how respiratory illnesses might influence vitamin D levels.

Healthy Participants1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesAllergologyDermatologyEndocrinologyInfectious DiseasesInternal MedicineNephrologyOphthalmologyOtolaryngologyPediatricsPsychiatryPulmonology

Chronic Rhinosinusitis with Nasal Polyps: Tapering Biologics

We are studying whether patients with stable chronic rhinosinusitis can safely reduce their biologic medication dosage after a year. This trial compares the effects of Mepolizumab and Dupilumab on disease control.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Metastatic Uveal Melanoma: Liver Radiotherapy with Tebentafusp

We are studying if adding liver-directed radiotherapy to the standard treatment helps patients with metastatic uveal melanoma live longer and stay on treatment longer. This trial also looks at how the body responds to the combination therapy.

Metastatic Uveal MelanomaEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Rezafungin for Fungal Infections in Critically Ill Patients

We are studying how Rezafungin levels change in patients on ECMO, a life-support treatment. This research aims to understand its effectiveness and any potential side effects.

Invasive Candidiasis>2 yearsConfirmation phase (III)Monitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal MedicinePulmonology

Multiple Myeloma: Comparing Treatment Approaches

We are studying two treatment plans for newly diagnosed multiple myeloma patients who cannot have a transplant. Our goal is to see which plan helps more patients reach a state of minimal disease.

Multiple MyelomaConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Cerebrospinal Fluid Disorders: MRI Contrast Agent Study

We are testing a new MRI contrast agent to assess cerebrospinal fluid flow in adults with CSF disorders. This may help improve diagnosis and treatment of central nervous system conditions.

Idiopathic Intracranial HypertensionIntracranial CystsPrimary or Secondary Brain Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurologyOtolaryngology

Botox for Hidradenitis Suppurativa Treatment

We are studying whether Botox can help reduce symptoms in patients with Hidradenitis Suppurativa. This trial will assess changes in skin condition and patient satisfaction over several months.

Hidradenitis SuppurativaMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesAllergologyDermatology

CART84 Treatment for Relapsed Acute Leukemias

We are studying a new infusion treatment called CART84 for patients with relapsed or refractory acute myeloid leukemia and acute lymphoblastic T leukemia. The goal is to evaluate its safety and effectiveness in helping patients achieve remission.

Relapsed/Refractory Acute Lymphoblastic T Leukemia (T-ALL)Relapsed/Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Infective Endocarditis: Oral vs. Parenteral Antibiotics

We are comparing oral antibiotics to outpatient parenteral antibiotics for treating infective endocarditis. The goal is to see if oral treatment is as effective and to assess patient satisfaction and costs.

Infective Endocarditis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInfectious Diseases

Rheumatoid Arthritis: Lower Dose of Rituximab Study

We are evaluating whether a 200 mg dose of Rituximab every six months is as effective as the standard 1 g dose for managing rheumatoid arthritis. This study will help us understand its impact on disease activity and overall patient well-being.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementRheumatology

Breast Cancer Prevention: Exemestane vs. Tamoxifen

We are comparing two low-dose medications for post-menopausal women at high risk for breast cancer to see which one may improve quality of life and hormonal balance. This study aims to understand their effects over 12 months.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Bladder Cancer: EMDA-MMC Treatment Study

We are evaluating a new treatment using electric current to deliver mitomycin C for high-grade non-muscle invasive bladder cancer. This study compares its effectiveness and safety to the standard BCG therapy.

Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology